Contact: Mike Wanner
Abeome Corporation
(706) 248-6098
mike.wanner@abeomecorp.com

November 30, 2007

Abeome and Millipore Launch Monoclonal Antibody for Stem Cell Research

Athens, GA - Abeome Corporation, a Georgia-based biotech company, today announced the launch of a unique stem cell monoclonal antibody (mAb) for distribution through Millipore Corporation.

Under the agreement between Abeome and Millipore, Millipore is granted an exclusive worldwide license to market and distribute the antibody for research use. Abeome received an upfront payment and will also receive royalties on sales by Millipore.

This initial antibody was developed by Abeome in collaboration with Novocell, Inc. The antibody's target is a cell surface protein that may prove to be a unique and important antigen. The target protein appears to be present on five human embryonic cell lines, but does not appear to be expressed on most differentiated cell types or common feeder cells. Scientists will use this antibody to help identify specific cell types that may be important in cancer therapeutic and diagnostic research.

The antibody, Human Embryonic Stem Cell Antigen-1 (HESCA-1) is available for sale through Millipore's web site, www.millipore.com, or by phone, 800-437-7500.

"Abeome is excited about the research potential for this antibody and the opportunity to work with Millipore. We anticipate launching several other mAb's through Millipore in the coming months." states Mike Wanner, President and CEO of Abeome.

About Abeome
Abeome Corporation is a biotechnology company dedicated to leveraging its proprietary hybridoma technology to accelerate and improve the development of monoclonal antibodies for life sciences. Its technology was invented at the University of Georgia by Richard Meagher, Ph.D. Abeome owns an exclusive license for the technology from the University of Georgia Research Foundation. For more information on Abeome, visit http://www.abeomecorp.com.

About Millipore

Millipore (NYSE: MIL) is a Life Science leader providing cutting-edge technologies, tools, and services for bioscience research and biopharmaceutical manufacturing. As a strategic partner, we collaborate with customers to confront the world's challenging human health issues. From research to development to production, our scientific expertise and innovative solutions help customers tackle their most complex problems and achieve their goals. Millipore Corporation is an S&P 500 company with more than 6,100 employees in 47 countries worldwide. For more information, please contact Millipore Tech Service at 1-800-548-7853 or 951-676-8080 or visit www.millipore.com.